title: Effects of chromium picolinate supplementation on insulin sensitivity, serum lipids, and body composition in healthy, nonobese, older men and women.
abstract: BACKGROUND
  Chromium is an essential nutrient required for carbohydrate and lipid metabolism. Chromium supplementation in humans has been reported to improve glucose metabolism and improve serum lipid parameters and to reduce body fat; parameters that worsen with aging. As a result, chromium picolinate has been widely promoted as a health aid for the general population. The purpose of the study was to examine the effects of chromium supplementation on insulin sensitivity, serum lipids, and body composition in nonobese, healthy men and women of advanced age.
  
  
  METHODS
  A randomized, double-blind, placebo-controlled study with 19 subjects (9 men and 10 women), aged 63-77, were given either chromium picolinate, 1,000 microg/d, or a placebo for 8 weeks. Serum lipids were measured at baseline and 8 weeks. Insulin sensitivity and body composition were measured with the minimal-model intravenous glucose tolerance test and dual-energy x-ray absorptiometry scan, respectively, at baseline and after 8 weeks of chromium or placebo supplementation.
  
  
  RESULTS
  No significant change in serum lipids, insulin sensitivity, or body composition was observed in the chromium group compared with the placebo group.
  
  
  CONCLUSIONS
  Chromium picolinate supplementation alone does not appear to improve insulin sensitivity, serum lipids, or change body composition in nonobese, healthy men and women of advanced age.
authors.affiliation: Department of Reproductive Medicine, University of California, San Diego, La Jolla 92093-0633, USA. pamato@ucsd.edu
authors.forename: P
authors.initials: P
authors.lastname: Amato
authors.forename: A J
authors.initials: AJ
authors.lastname: Morales
authors.forename: S S
authors.initials: SS
authors.lastname: Yen
mesh_terms: D015502:Absorptiometry, Photon; D000368:Aged; D000704:Analysis of Variance; D001823:Body Composition / Q000187:drug effects*; D019587:Dietary Supplements; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007328:Insulin / Q000097:blood*; D007502:Iron Chelating Agents / Q000008:administration & dosage*; D008055:Lipids / Q000097:blood*; D008297:Male; D010848:Picolinic Acids / Q000008:administration & dosage*; D011863:Radioimmunoassay
chemical_list: D007328:Insulin; D007502:Iron Chelating Agents; D008055:Lipids; D010848:Picolinic Acids; C030614:picolinic acid